Tuesday, November 01, 2022 10:45:28 AM
ENGLEWOOD, Colo., Nov. 1, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common stock. The program will commence on November 1, 2022 and is scheduled to terminate on October 31, 2023 or when the $10.0 million buyback limit is reached.
Zynex
Zynex
"We are committed to driving long-term value for our shareholders and believe that the current strength of our balance sheet presents a strategic opportunity for a third buyback program," said Thomas Sandgaard, founder, and CEO of Zynex. "We've repurchased $20 million of our common stock thus far in 2022 and an additional $10 million share buyback reiterates our commitment to creating value. We believe our consistent performance and ability to maintain profitability is not reflected in Zynex's market valuation and are initiating this buyback program as an attractive opportunity to deploy capital and return value to our shareholders."
Under the share buyback program, buybacks may be made from time-to-time in open market and negotiated purchases, effective immediately through the next twelve months. These buybacks will be made in compliance with the SEC's Rule 10b-18, subject to market conditions, available liquidity, cash flow, applicable legal requirements, and other factors. The specific prices, numbers of shares, and timing of purchase transactions will be determined by the Company from time to time in its sole discretion. This program does not obligate the Company to acquire any particular amount of common stock, and the program may be suspended or discontinued at any time, including in the event the Company would be deemed to be making an acquisition of its own shares under Rule 13e-3 of the Securities Exchange Act of 1934, as amended.
The Company expects to finance the purchases with existing cash balances, which is not expected to have a material impact on capital levels.
Zynex, Inc. had approximately 41.6 million shares issued and 37.5 million shares outstanding as of November 1, 2022.
Recent ZYXI News
- Zynex Sets First Quarter 2024 Earnings Call • PR Newswire (US) • 04/18/2024 01:15:00 PM
- Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award • PR Newswire (US) • 04/02/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:15:17 PM
- Zynex Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 02/29/2024 09:01:00 PM
- Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call • PR Newswire (US) • 02/22/2024 02:15:00 PM
- Zynex Introduces New Products • PR Newswire (US) • 02/20/2024 02:15:00 PM
- Sichenzia Ross Ference Carmel LLP Closes Over 100 Capital Markets Transactions Valued At Over $700 Million in 2023 • GlobeNewswire Inc. • 02/08/2024 02:00:00 PM
- Zynex Receives FDA Clearance for its Next Generation NMES Device • PR Newswire (US) • 02/06/2024 02:15:00 PM
- Zynex Recognized in Top 25 Medical Device Companies for 2024 • PR Newswire (US) • 02/02/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:55:32 PM
- Zynex to Participate at the Needham Annual Growth Conference • PR Newswire (US) • 01/08/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:15:06 PM
- Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024" • PR Newswire (US) • 11/15/2023 02:15:00 PM
- Zynex Submits FDA Application for its Next Generation NMES Device • PR Newswire (US) • 11/13/2023 02:15:00 PM
- Zynex Named as a Winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th Consecutive Year • PR Newswire (US) • 11/09/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 01:20:20 PM
- Zynex Announces Share Repurchase Program • PR Newswire (US) • 11/01/2023 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 10:50:12 AM
- Zynex Announces Review of Strategic Alternatives • PR Newswire (US) • 10/31/2023 10:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 09:01:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:05:38 PM
- Zynex Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 10/26/2023 08:01:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM